BR112023004123A2 - Vacina de haste da ha para alvos positivos de anticorpos de ha - Google Patents

Vacina de haste da ha para alvos positivos de anticorpos de ha

Info

Publication number
BR112023004123A2
BR112023004123A2 BR112023004123A BR112023004123A BR112023004123A2 BR 112023004123 A2 BR112023004123 A2 BR 112023004123A2 BR 112023004123 A BR112023004123 A BR 112023004123A BR 112023004123 A BR112023004123 A BR 112023004123A BR 112023004123 A2 BR112023004123 A2 BR 112023004123A2
Authority
BR
Brazil
Prior art keywords
vaccine
influenza virus
vector
stem
disease
Prior art date
Application number
BR112023004123A
Other languages
English (en)
Inventor
Alexander Langereis Martijn
Verstegen Iwan
Alexander Maria De Haan Cornelis
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112023004123A2 publication Critical patent/BR112023004123A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

VACINA DE HASTE DA HA PARA ALVOS POSITIVOS DE ANTICORPOS DE HA. A presente invenção está relacionada a vacinas contra a infecção ou doença pelo vírus influenza para alvos com anticorpos pré-existentes contra o domínio da cabeça da HA do vírus influenza. A invenção considera um vetor recombinante expressando um polipeptídeo da haste da HA, uma vacina compreendendo o vetor ou uma célula hospedeira com o referido vetor, usos do vetor, da célula hospedeira ou da vacina e métodos para reduzir a infecção ou doença pelo vírus influenza. O vetor recombinante pode ser um ácido nucleico tal como um plasmídeo de expressão eucariótica ou um RNA, um vírus ou uma partícula de replicon (RP). Essa vacinação permite a indução de uma resposta imunológica precoce e eficaz contra a infecção ou doença induzida pelo vírus Influenza, não impedida por anticorpos de domínio de cabeça anti-HA pré-existentes.
BR112023004123A 2020-09-07 2021-09-06 Vacina de haste da ha para alvos positivos de anticorpos de ha BR112023004123A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20194937 2020-09-07
PCT/EP2021/074446 WO2022049276A1 (en) 2020-09-07 2021-09-06 Ha stem vaccine for ha antibody-positive targets

Publications (1)

Publication Number Publication Date
BR112023004123A2 true BR112023004123A2 (pt) 2023-04-04

Family

ID=72428193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004123A BR112023004123A2 (pt) 2020-09-07 2021-09-06 Vacina de haste da ha para alvos positivos de anticorpos de ha

Country Status (9)

Country Link
US (1) US20240024456A1 (pt)
EP (1) EP4210740A1 (pt)
JP (1) JP2023539771A (pt)
KR (1) KR20230065321A (pt)
CN (1) CN116528893A (pt)
BR (1) BR112023004123A2 (pt)
CA (1) CA3190070A1 (pt)
MX (1) MX2023002674A (pt)
WO (1) WO2022049276A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961982A (en) 1985-09-06 1999-10-05 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
FR2749022B1 (fr) 1996-05-23 2001-06-01 Rhone Merieux Cellules aviaires immortelles
US5672485A (en) 1996-08-13 1997-09-30 Regents Of The University Of Minnesota Immortalized cell lines for virus growth
JP5065024B2 (ja) 2004-05-18 2012-10-31 アルファバックス，インコーポレイティド Ｔｃ−８３由来アルファウイルスベクター、粒子および方法
KR20080103602A (ko) 2006-03-15 2008-11-27 인터벳 인터내셔널 비.브이. 재조합 모노네가바이랄러스 바이러스 벡터
PL2947149T3 (pl) 2007-06-21 2018-09-28 Alphavax, Inc. Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US8986987B2 (en) 2010-10-18 2015-03-24 Intervet Inc. Herpesvirus of turkeys vectored vaccine against avian influenza in poultry
US9012424B2 (en) 2011-05-27 2015-04-21 20Med Therapeutics B.V. Nanogels
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
MY182440A (en) * 2014-07-10 2021-01-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP6546659B2 (ja) 2014-12-04 2019-07-17 インターベット インターナショナル ベー． フェー． 不死化ニワトリ胚線維芽細胞
AR103245A1 (es) 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
JP7354106B2 (ja) 2017-12-04 2023-10-02 インターベット インターナショナル ベー． フェー． レプリコン粒子および油性アジュバントによるワクチン接種
CN111542337A (zh) 2017-12-20 2020-08-14 英特维特国际股份有限公司 用于细胞相关联的α疱疹病毒疫苗的改良稀释剂

Also Published As

Publication number Publication date
CN116528893A (zh) 2023-08-01
CA3190070A1 (en) 2022-03-10
EP4210740A1 (en) 2023-07-19
US20240024456A1 (en) 2024-01-25
KR20230065321A (ko) 2023-05-11
JP2023539771A (ja) 2023-09-19
WO2022049276A1 (en) 2022-03-10
MX2023002674A (es) 2023-04-03

Similar Documents

Publication Publication Date Title
CO2021004188A2 (es) Vacuna contra el virus de la peste porcina africana
ES2555959T3 (es) Procedimiento de fabricación de vacunas virales en líneas de células madre derivadas de embriones aviares en suspensión
MX2013004303A (es) Vacuna vectorizada por el herpesvirus de los pavos contra la influenza aviar en aves de corral.
Schotsaert et al. Influenza vaccines: T-cell responses deserve more attention
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
US9017694B2 (en) Swine influenza hemagglutinin variants
BR112017013595A2 (pt) cassete de expressão de dna recombinante, molécula de dna recombinante, vírus herpes de peru recombinante, célula hospedeira, métodos para construção de um vírus herpes de peru recombinante, para preparação de uma vacina, para prevenir ou reduzir infecção por vírus da doença bursal infecciosa e/ou vírus da doença de newcastle ou sinais associados de doença e para vacinação das aves, vacina para aves, e, usos de um cassete de expressão e de uma vacina.
Trucchi et al. Universal influenza virus vaccines: what needs to happen next?
Wei et al. Development and characterization of a recombinant infectious bronchitis virus expressing the ectodomain region of S1 gene of H120 strain
BR112015025898A2 (pt) polipeptídeo, célula, ácido nucleico, vetor, vírus da varíola suína recombinante, composição, vacina, e uso de um peptídeo sinal
Kotomina et al. Live attenuated influenza vaccine viral vector induces functional cytotoxic T-cell immune response against foreign CD8+ T-cell epitopes inserted into NA and NS1 genes using the 2A self-cleavage site
EA201791957A1 (ru) Маркерная система, в частности, для экспрессируемых бакуловирусом субъединичных антигенов
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
Jazi et al. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine
Kaplan et al. Vaccination of pigs with a codon-pair bias de-optimized live attenuated influenza vaccine protects from homologous challenge
BR112023004123A2 (pt) Vacina de haste da ha para alvos positivos de anticorpos de ha
Zhou et al. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1
BR112018003580A2 (pt) molécula de ácido nucléico, método para apresentar um polipeptídeo alvo, proteína recombinante, partícula do tipo viral, composição farmacêutica, polipeptídeo, vetor, célula hospedeira e método para preparar a proteína recombinante
Hasegawa et al. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
BR112018075585A2 (pt) spv recombinante multivalente
Schmidt et al. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase
Qin et al. Biological characteristics and immunological properties in Muscovy ducks of H5N6 virus-like particles composed of HA-TM/HA-TMH3 and M1
Jiang et al. Protective efficacy of H7 subtype avian influenza DNA vaccine
JP6373601B2 (ja) アカバネウイルスに対して中和活性を有する抗体を誘導するペプチド
ECSP14023407A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él